StockWatch
·
Pharmaceuticals
Quarterly Result5 Nov 2026, 01:50 pm

Fermenta H1FY27 Revenue Down 7% YoY to ₹261.9 Cr

AI Summary

Fermenta Biotech Limited reported unaudited financial results for H1FY27, with consolidated revenue at INR 261.9 crore, a 7% decrease year-on-year. EBITDA fell by 34% YoY to INR 45.6 crore, and Profit After Tax declined by 52% YoY to INR 18.9 crore. The decrease in revenue and EBITDA is primarily attributed to lower animal nutrition business performance and one-off income in the prior year, including insurance claims and real estate value unlocking. The company noted a shift in revenue mix, with India's contribution rising to 51% from 40% a year earlier, indicating a focus on steadier markets. The Human Nutrition segment grew by 2% in revenue share, now comprising close to two-thirds of overall revenue. Key developments include FSSAI approval for VITADEE Green® and the company's listing on the NSE. The company expects its Vitamin D3 analog product, Calcifediol, to be ready for regulatory approvals by the end of FY27.

Key Highlights

  • Consolidated revenue for H1FY27 decreased 7% YoY to INR 261.9 crore.
  • EBITDA and PAT saw significant YoY declines of 34% and 52% respectively.
  • Human Nutrition segment's revenue share increased, now nearing two-thirds of total revenue.
  • India emerged as the largest market, contributing 51% of consolidated revenue.
  • VITADEE Green® received FSSAI approval, expanding market potential for Vitamin D3.